Improved Responses with Azacitidine Compared to Decitabine in Patients with Acute Myeloid Leukemia in Patients ≥70 with Poor-Risk Cytogenetics

Therapeutic options for patients age ≥70 years with acute myeloid leukemia (AML) are extremely limited and comprise mainly of clinical trials and hypomethylating agents (HMAs) including azacitidine (AZA) and decitabine (DEC). Thus we aim to explore clinical outcomes when treated with AZA compared to DEC.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Chetasi Talati, Andrew Kuykendall, Najla Al-Ali, Rami Komrokji, Eric Padron, David Sallman, Alan List, Kendra Sweet, Martine Extermann, Jeffrey Lancet Source Type: research